US court suspends permanent injunction for Praluent pending appeal

9 February 2017

The US Court of Appeals for the Federal Circuit has stayed (suspended) the permanent injunction for Praluent (alirocumab) Injection granted last month in a patent infringement dispute with US biotech Amgen (Nasdaq: AMGN) pending the appeal that French pharma major Sanofi (Euronext: SAN) and its partner Regeneron (Nasdaq: REGN) plan to file.

This ruling (available here) means that Sanofi and Regeneron will continue marketing, selling and manufacturing the cholesterol-lowerer Praluent in the USA during the appeal process. Sanofi and Regeneron remain committed to ensuring patients who can benefit from Praluent continue to have access to this innovative therapy.

Without the stay, Praluent - which rolled out in the USA, Europe and Japan over 2015/6 and generated sales of 105 million euros ($112 million) in 2016 - would have been forced off the US market on February 21. Sanofi’s shares edged up 1.8% to 78.03 euros by late-morning trading today.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK